Immobilized HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His & Avi, Human, His Tag at 0.5 μg/ml (100 μl/well) on the plate. Dose response curve for Anti-HLA-G Antibody, hFc Tag with the EC50 of 5.7 ng/ml determined by ELISA.

The purity of HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His & Avi, Human is greater than 90% as determined by SEC-HPLC.

HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.

Serial dilutions of Anti-LILRB2 Antibody were added intoHLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His & Avi, Human, His Tag : Human LILRB2, mFc Tag binding reactioins. The half maximal inhibitiory concentration(IC50) is 70.0 ng/ml.

Human LILRB2, hFc Tag captured on CM5 Chip via Protein A can bind HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His & Avi, Human with an affinity constant of 4.62 nM as determined in SPR assay (Biacore T200).

HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His & Avi, Human, His Tag immobilized on CM5 Chip can bind Human LILRB2 Domain1&2, His Tag with an affinity constant of 6.5μM as determined in a SPR assay (Biacore T200).

HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His & Avi, Human

HLA-G is a molecule that was first known to confer protection to the fetus from destruction by the immune system of its mother, thus critically contributing to fetal-maternal tolerance. The first functional finding constituted the basis for HLA-G research and can be summarized as such: HLA-G, membrane-bound or soluble, strongly binds its inhibitory receptors on immune cells (NK, T, B, monocytes/dendritic cells), inhibits the functions of these effectors, and so induces immune inhibition.

Cat. No.	Z06649
Size	100 μg : Quote 500 μg : Quote Buy in bulk
Quantity
Price	¥208,928.00


Ask us a question

Product Introduction

Species

Human

Protein Construction

HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer[Gly25-Thr305(HLA-G), Ile21-Met119(B2M) and RIIPRHLQL peptide] Accession # P17693-1(HLA-G)&P61769(B2M)&RIIPRHLQL	His	Av
N-term		C-term

Purity

> 95% as determined by BisTris PAGE
> 90% as determined by HPLC

Endotoxin Level

Less than 1EU per μg by the LAL method.

Biological Activity

Measured by its binding ability in a functional ELISA. Immobilized HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His & Avi, Human at 0.5μg/ml (100μl/well) on the plate can bind AntiHLAG Antibody, hFc Tag. Test result was comparable to standard batch.

Expression System

HEK293

Theoretical Molecular Weight

258 kDa

Apparent Molecular Weight

Due to glycosylation, the protein migrates to 260-265 kDa under Non reducing (N) condition based on Bis-Tris PAGE result.

Formulation

Lyophilized from 0.22μm filtered solution in PBS (pH 7.4).

Reconstitution

Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.

Storage & Stability

Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles.

Examples

The purity of HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His & Avi, Human is greater than 90% as determined by SEC-HPLC.

HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His & Avi, Human on Bis-Tris PAGE under Non reducing (N) condition. The purity is greater than 95%.

Background

Target Background

Synonyms

HLA G antigen; sHLA-G; b2 microglobulin; HLA G; HLAG; HLA-G; MHC Class I Antigen G; MHC class Ib antigen; MHC-G; sHLA-G

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.

HLA-G&B2M&Peptide (RIIPRHLQL) Tetramer, His & Avi, Human

サポート

会社情報

サポート

会社情報